FDA's Adverse Event Surveillance Systems and MedWatch

Gerald J. Dal Pan, MD, MHS
Director, Office of Surveillance and
Epidemiology

50-State Meeting 21 March 2014

Purpose of Postmarketing Safety Reporting

To learn about new risks


To learn more about known risks

To learn about medication errors


To learn how patterns of use may contribute to unsafe use

To learn about product quality problems

Sources of Drug Safety Information



How Adverse Event Reports Get to FDA



Reporting Adverse Events to FDA

Industry

ICH E2B electronic standard

MedWatch form 3500A

Public

MedWatch 3500

MedWatch 3500B

ICH E2B Standard

- Internationally harmonized standard
- For use by industry
- About 90% of adverse event reports are through the ICH E2B standard
- May not be suitable for firms with low reports volumes
 - FDA is exploring alternative ways for manufacturers to submit reports electronically


Guidance for Industry

E2BM Data Elements for Transmission Of Individual Case Safety Reports

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) April 2002


> > ICH Revision 1


MedWatch Form 3500




- MedWatch Form 3500
 - Designed for use by the public
 - Not consumer friendly
 - Best for healthcare professionals
- Four main elements
 - Patient
 - Product
 - Event
 - Reporter


MedWatch Form 3500A







MedWatch Form 3500A



- Designed for use by industry
- Lots of fields not present on other MedWatch forms
- Some fields are exclusively for devices

Consumer MedWatch Form

Food and Drug Administration MEDWATCH Consumer Volunta (FORM FDA 3500B)			
Section A — What kind of problem was it? (Check all that apply) Were hurt or had a bad side effect (including new or worsening symptoms) Used a product incorrectly which could have or led to a problem Noticed a problem with the quality of the product Had problems after switching from one product maker to another maker	About the Problem Did any of the following happen? (Check all that apply) Hospitalization — admitted or stayed longer Required help to prevent permanent harm (for medical devices only) Disability or health problem Birth defect Life threatening Death (Include date): Other's erious/important medical incident (Please describe below)		
List any relevant tests or laboratory data if you know them. <i>linok</i>	Couth sation		
For a problem with a product, including prescription or over-the-counter medicine biologics, such as human cells and tissues used for trans (for example, tendons, ligaments, and bone) and gene th nutrition products, such as vitamins and minerals, herbal formulas, and medical foods cosmetics or make-up products foods (including beverages and ingredients added to food	erapies Go to Section B remedies, infant		
For a problem with a medical device, including any health-related test, tool, or piece of equipment health-related kits, such as glucose monitoring kits or blo implants, such as breast implants, pacemakers, or cathet other consumer health products, such as contact lenses, breast pumps	ters (Skip Section B)		

- MedWatch Form 3500B
- Introduced mid-2013
- User-friendly format for non-health care professionals
- Includes 4 minimum elements
 - Patient
 - Product
 - Event
 - Reporter
- Captures other information included on the 3500, but asks for it in a more consumer-friendly way.

Submission of a report does not constitute an admission that medica

Updating the MedWatch Forms

- MedWatch form has expiration dates
 - Require periodic renewal
- FDA staff determine if and how the MedWatch form needs to be changed
 - Program needs drive the changes
- Changes require extensive review

Form Approved: OMB No. 0910-0291, Expires: 6/30/2015
See OMB statement on reverse.

Mfr Report #

UF/Importer Report #

FDA Use Only


Qualities of a Good Case Report

- What makes a good case report?
 - Description of the event
 - Suspected product(s) and concomitant treatment details
 - Patient characteristics, medical history, treatment history
 - Documentation of the diagnosis
 - Clinical course and outcomes
 - Treatment and lab values at baseline, during therapy, and after therapy
 - Response to dechallenge and rechallenge
 - Any other relevant information
- This takes time

FDA Adverse Event Reporting System (FAERS)

- Computerized database
 - Informatic structure adheres to ICH standards
- Contains human drug and therapeutic biologic reports
- Adverse events, medication errors, and indications are coded to terms in Medical Dictionary for Regulatory Activities (MedDRA)
- Products are coded using the FAERS Product Dictionary
- Public extract is released quarterly





Adverse Event Data are Incorporated into Product Labels

Table. Results From Quarterly Reports From January 2008 to December 2010


Result	Quarterly Reports, Year, No. (%)			
	2008	2009	2010	Total
Potential safety signals, No.	60	45	48	153
_abel changes	30 (50)	28 (62)	16 (33)	74 (48) ^b
Subgroups ^a	, ,	, ,	,	, ,
Warnings and Precautions	16 (53)	19 (68)	11 (69)	46 (62)
Adverse Reactions	11 (37)	5 (18)	7 (44)	23 (31)
Drug Interactions	2 (7)	1 (4)	0	3 (4)
Dosage and Administration	1 (3)	1 (4)	0	2 (3)
Boxed Warning	6 (20)	2 (7)	1 (6)	9 (12)
Contraindications	0	1 (4)	1 (6)	2 (2)
Use in Specific Populations	0	0	1 (6)	1 (1)
REMS	2 (7)	2 (7)	0 `	4 (5)
Withdrawn from market	0 ` ′	0 `	1 (6)	1 (1)

Abbreviation: REMS, Risk Evaluation Mitigation Strategy.

^aCalculated from the number of actual label changes.

^bThe calculated 48% total label changes includes the 1 drug withdrawn from the market and those drugs with newly implemented REMS.

Percentage of safety-related label changes in the United States by data source - 2010



Public Data Extracts – What data are released?

- ~200,000 reports each quarter
- Over 50 data elements as reported from each case in the following area's:

Key Areas	Type of data
Demographics	E.g. age, weight
Drug characteristics	E.g. drug name, dose, strength
Indication	MedDRA code of the indication for which the patient was treated
Outcome	E.g. hospitalization, death, life threatening
Reaction	MedDRA code for the drug reaction
Report Sources file	Health Professional, Study, Literature, Consumer etc.
Therapy Dates	E.g. start and end of drug therapy

Public Data Extract – What data are not released?

- Personal Identifiable Information (PII)
 - Data should not make it possible to identify individual patients
- "Narrative" As it may contain, names, initials, phone number or other personal identifying information (PII)
 - "Narrative" is where the reporter describes the drug reaction in their own words
- Patient's address or the state
 - We do release the country the event occurred or reported in
- Death date
- Dates like the onset date and the drug therapy dates are released but not dates like reaction dates which may, in some cases, imply a death date

Data Element - State

- 3 data elements related to state
 - Reporter State
 - Captured if reported by the reporter
 - Sender Organization State (Mfr.'s regulatory group send the AE)
 - Captured as part of the mandatory AE report
 - Product Manufacturer State (where product manufactured)
 - Only in reports submitted by industry
 - None of the state information is released as part of Public Data Extract

Compounded Product in FAERS

- Central Triage Unit identifies compounded products only from direct reports
 - "Compounded" is captured in the database
- Compounded products are coded to its active ingredient(s)
 - Discern from the report or by searching the web
 - No unique prefix or suffix identifying the ingredient as compounded
- "Compounded" identifier can be used as a search parameter

Questions?